Login to Your Account

Cytokinetics sees tirasemtiv hopes dashed in phase III ALS trial miss

By Michael Fitzhugh
Staff Writer

Tuesday, November 21, 2017

Cytokinetics Inc. is suspending development of its lead candidate, tirasemtiv, for ALS after it failed to hit both primary and secondary endpoints in a crucial phase III test.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription